2021_1025 Dawn Bell 228323.jpg


Executive Profile

Dr. Dawn Bell is a global, strategic, biopharmaceutical executive (NYSE: NVS), Board Director, GM, and CEO with demonstrated success as an operator and advisor across the drug development value chain. She has 20+ years of proven success starting and scaling life-science businesses from academic spinouts to Top 5 Pharma.  She provides rapidly growing companies insights on corporate strategy, value creation, business development, team building, and culture. She is a board director and advisor for privately held life-science companies, research institutes, CEOs, founders, and innovation accelerators in the US and Europe.

Career Highlights

  • Delivered Entresto ($3.5B) approval 18 months ahead of schedule as GM. Led 100+ person team responsible for global strategy, regulatory approval, and reimbursement.  Secured Break-Through and Fast-Track status at the FDA.

  • Led sell-side BD&L and successful out-licensing of novel biologic for rare hematologic disorders; Buy-side BD&L experience at Novartis leading white space portfolio strategy with full visibility into BD&L and M&A decision-making and governance processes.

  • As member of the Executive Team for Novartis Canada, led launch prep for 9 new medicines across 5 therapeutic areas in 4 years (Mayzent, Kesimpta, Zolgensma, Beovu, Luxturna, fevipiprant, early NASH portfolio, pelacarsen, Inclisiran).  Built the team that launched 1st gene therapies approved in Canada.

  • Founding CEO of Emory University spinout. Led fundraising, company build, IP license and Duke University research collaboration negotiations.

  • Early commercial leader at The Medicines Company (NASDAQ:  MDCO) contributing to market cap growth from $400M to >$2B over 3 years.

Board Service

TMIC:  Guided National Research Consortium through critical restructure and renewal of Federal Funding.

Gold Track: Helped ventures raise over €500M, secure 24 partnerships and achieve three exits totaling over €1B in 4 years. Companies include Ochre Bio ($9.6M seed led by Khosla) and Phagomed (acquired by BioNTech).

Awards and Honors

University of Florida College of Pharmacy Alumnus of the Year, 2022.

Awarded for extraordinary accomplishments and exceptional achievements which have brought pride, honor, and recognition to the College.

Creative Destruction Lab, Mentor of the Year Toronto, 2018

Selected by founder-led, science-based start-up ventures out of 100+ mentors.